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Abstract
Introduction: Community-acquired pneumonia (CAP) account for a high proportion of ICU admissions, with
Streptococcus pneumoniae being the main pathogen responsible for these infections. However, little is known on
the clinical features and outcomes of ICU patients with pneumococcal pneumonia. The aims of this study were to
provide epidemiological data and to determine risk factors of mortality in patients admitted to ICU for severe
S. pneumoniae CAP.
Methods: We performed a retrospective review of two prospectively-acquired multicentre ICU databases (2001-
2008). Patients admitted for management of severe pneumococcal CAP were enrolled if they met the 2001
American Thoracic Society criteria for severe pneumonia, had life-threatening organ failure and had a positive
microbiological sample for S. pneumoniae. Patients with bronchitis, aspiration pneumonia or with non-pulmonary
pneumococcal infections were excluded.
Results: Two hundred and twenty two patients were included, with a median SAPS II score reaching 47 [36-64].
Acute respiratory failure (n = 154) and septic shock (n = 54) were their most frequent causes of ICU admission.
Septic shock occurred in 170 patients (77%) and mechanical ventilation was required in 186 patients (84%); renal
replacement therapy was initiated in 70 patients (32%). Bacteraemia was diagnosed in 101 patients. The prevalence
of S. pneumoniae strains with decreased susceptibility to penicillin was 39.7%. Although antibiotherapy was
adequate in 92.3% of cases, hospital mortality reached 28.8%. In multivariate analysis, independent risk factors for
mortality were age (OR 1.05 (95% CI: 1.02-1.08)), male sex (OR 2.83 (95% CI: 1.16-6.91)) and renal replacement
therapy (OR 3.78 (95% CI: 1.71-8.36)). Co-morbidities, macrolide administration, concomitant bacteremia or penicillin
susceptibility did not influence outcome.
Conclusions: In ICU, mortality of pneumococcal CAP remains high despite adequate antimicrobial treatment.
Baseline demographic data and renal replacement therapy have a major impact on adverse outcome.
Introduction
Community-acquired pneumonia (CAP) is a frequent
and severe infection, and is considered the primary
cause of death from infection, and the sixth most com-
mon cause of overall mortality in Western countries
[1,2]. Consequently, CAP represents one of the leading
causes of infectious admissions to the intensive care
unit (ICU) [3]. Indeed, the latest studies have reported
that up to 10 % of all patients hospitalised with CAP
require ICU management [4]. In this specific subgroup
of severely ill patients, the overall mortality rate remains
unacceptably high despite improvement in critical care
management [5]. Furthermore, the medical burden of
CAP is very high in terms of direct costs, associated
morbidity and long-term disability [6,7].
Streptococcus pneumoniae (S. pneumoniae) is the prin-
cipal causative agent of CAP requiring hospital or ICU
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admission [8]. Paediatric and adult literature about non-
severe pneumococcal pneumonia is abundant, but speci-
fic data on patients requiring ICU admission are scarce.
In the two studies focusing on the epidemiology of
pneumococcal pneumonia among patients admitted to
ICU, co-morbidities negatively influenced patient out-
comes, but were over-weighted by the severity of the
clinical features [9,10]. Recent therapeutic researchers
have pointed out that early and adequate antibiotherapy
is of greatest importance during sepsis, whereas adjuvant
therapies like steroids or activated protein C may reduce
the fatality rate [11]. However, the roles of these anti-
inflammatory agents, as well as the association with
macrolides during severe pneumococcal pneumonia are
a matter of debate [12]. Thus, increased knowledge of
severe S. pneumoniae pneumonia that may improve
early detection and treatment of this particular subgroup
carries high interest for ICU physicians.
The aim of this present study was to provide recent
epidemiological data through a large cohort of adult
patients admitted to ICU for severe pneumococcal CAP.
In addition to analysis of microbiological features, we
assessed the respective influence of co-morbidity and
organ failure on mortality. We also investigated the
potential impact of adjuvant therapies on outcome.
Methods and materials
Study design
After approval from the local Cochin Hospital institu-
tional review board, patients were retrospectively selected
from two prospective cohorts including ICU patients
admitted with infection (one multicentre cohort and one
from the Cochin medical ICU) between January 2001
and June 2008. Informed consent was waived and
informed assessment was obtained from all patients or
next of kin before inclusion.
Inclusion and exclusion criteria
Inclusion criteria were 1) age over 18 years; 2) severe CAP
diagnosed according to the adapted American Thoracic
Society definition [13,14], which includes features consis-
tent with pneumonia (new or increased cough with or
without sputum production, tachypnoea, chest pain,
abnormal temperature (> 38°C or < 36°C) or lung consoli-
dation on physical examination), with either one of two
major criteria (need for mechanical non-invasive or inva-
sive ventilation or septic shock) or any two of three minor
criteria (involvement of more than two lobes on a chest
radiograph, systolic blood pressure < 90 mmHg or PaO2/
FIO2 ratio < 250 mmHg); 3) ICU hospitalisation required
for haemodynamic, respiratory or neurologic failure or
severe co-morbidities and 4) a microbiological sample
positive for S. pneumonia, that is, sputum examination
with a bacterial count ≥ 107 colony forming unit/mL
(CFU/mL) (fulfilling the usual quality criteria of > 25 poly-
morphonuclear leukocytes and < 10 epithelial cells per
low-power field, magnification × 100), or a microbiological
sample positive for S. pneumoniae in a normally sterile site
(a positive quantitative culture of endotracheal aspirate,
with a bacterial count ≥ 106 CFU/mL, a positive quantita-
tive culture of broncho-alveolar lavage with a bacterial
count ≥ 104 CFU/mL, or a protected specimen brush with
a bacterial count ≥ 103 CFU/mL, or a positive blood cul-
ture, or a positive pleural culture or a positive urinary
antigen).
Healthcare-associated pneumonia was not included.
Patients with bronchitis or aspiration pneumonia due to
S. pneumoniae and patients with concomitant pneumo-
coccal meningitis or endocarditis were excluded from
the study.
Study variables and outcomes
Data were prospectively collected, including demographic
characteristics, initial clinical presentation, usual biologi-
cal values, antibiotherapy management, organ failures
and outcomes were investigated. Septic shock was
defined as the requirement for vasopressor for more than
4 hours or hypotension (systolic blood pressure < 90
mmHg) for more than one hour despite adequate fluid
challenge plus either a change in mental status, oliguria,
organ dysfunction, or lactate > 2 mmol/L [15]. Acute
respiratory distress syndrome (ARDS) and multi-organ
failure were defined according to the usual criteria
[15,16]. Acute kidney injury was considered present if the
patient was considered to be in the Injury stage of the
Risk, Injury, Failure, Loss and End-stage disease (RIFLE)
criteria [17]. The Logistic Organ Dysfunction System
(LODS) score [18] and the Simplified Acute Physiology
Score II (SAPS II) [19] were also calculated. The follow-
ing therapeutic data were recorded: vasoactive drugs,
renal replacement therapy, activated protein C and low
doses of systemic corticosteroids.
All patients were followed up until death or hospital
discharge. Two independent investigators (NM and AM)
reviewed all files.
Susceptibility of the bacterial strains to penicillin G was
recorded according to the recommendations from the
Antibiogram Committee of the French Society for Micro-
biology (CA-SFM) [20] for antimicrobial susceptibility
testing and breakpoints and defined as susceptible: penicil-
lin minimal inhibitory concentration (MIC) ≤ 0.06 mg/L,
or intermediate: 0.06 mg/L < MIC ≤ 1 mg/L; resistant:
MIC > 1 mg/L.
Antibiotherapy was considered appropriate if the
initial empiric therapy had in vitro activity against the
isolated strain of S. pneumoniae. Pneumococcal vaccine
status was documented for less than 5% of the records
and thus was not included in the analysis.
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Statistical analysis
Continuous variables were expressed as median and
interquartile range, and categorical variables as number
and percentage. Continuous variables were compared
using the Mann-Whitney U-test and categorical vari-
ables were compared using the chi-square test. Indepen-
dent predictors of outcome were assessed using a
multivariate logistic regression model through a stepwise
forward procedure, where the variable of interest was
hospital mortality. Results were expressed as odds ratio
(OR) and 95% confidence interval (CI). For continuous
variables, the OR was indexed to an increment of one
unit. Categorical variables were expressed as absence or
presence. Goodness-of-fit of the final model was
assessed by the Hosmer-Lemeshow test. Statistical sig-
nificance was defined as P < 0.05. Analyses were per-
formed using PASW software (SPSS Inc., Chicago, ILL,
USA).
Results
Of the 3,658 patients enrolled in the two cohorts, 423
had positive microbiological samples for S. pneumoniae.
Among them, 133 had evidence of aspiration or bron-
chitis and 290 were subsequently screened. After the
exclusion of 68 patients with concomitant meningitis,
222 patients were finally included in this study.
Patients’ characteristics
Demographic characteristics and the main clinical fea-
tures of patients are reported in Table 1. Median
(range) SAPS II and LODS scores were respectively 47
(36 to 64) and 8 (5 to 10), thereby reflecting severe criti-
cal illness. Eighty-four patients had no tobacco or alco-
hol intoxication, and no coexisting illness. Twenty-three
patients had already experienced an invasive pneumo-
coccal infection in the past. Repartition of the disease
onset according to the season is represented in Figure 1,
with an incidence peak during autumn and winter.
Clinical features
Reasons for ICU admission were mainly acute respiratory
failure (n = 154), septic shock (n = 54), coma (n = 6) or
others (n = 8). Twenty-eight patients were admitted after
worsening of their clinical status in the ward. On admis-
sion, most patients had several organ dysfunctions with a
median organ failure score of 3 (range 2 to 4). During the
ICU stay, 157 patients (70.7%) had multi-organ failure.
Respiratory function was severely impaired with a median
PaO2/FiO2 ratio of 98 (73 to 149) at admission, and mul-
tilobar pneumonia was present in 68 patients (30.6%).
Non-invasive ventilation was initiated in 70 patients but
52 patients required secondary endotracheal intubation.
Overall, invasive ventilation was required for 186
patients, of whom 100 (45%) exhibited ARDS criteria.
In survivors, ventilator weaning was achieved after a
median of 8 (4 to 20) days.
In addition to severe hypoxemia, more than 50% of
the patients had elevated plasma lactate concentrations
and one fourth of the patients presented other biological
severity signs such as leucopoenia or disseminated intra-
vascular coagulation criteria (Table 1).
During the course of pneumonia, 170 patients (76.6%)
developed septic shock, catecholamine infusion was
required for a median of 3 (0 to 7) days. At admission,
acute kidney injury was present in 87 patients and renal
replacement therapy was initiated in 70 patients (31.5%).
Median mechanical ventilation-free, catecholamine-free
and renal replacement therapy-free days were respec-
tively 3 (1 to 6), 7.5 (3 to 16) and 12 (4 to 19) days. Adju-
vant therapies, including low dose steroids or activated
protein C, had been initiated in 69 (31%) and 44 (20%)
patients respectively.
Microbiological data and antibiotherapy
S. pneumoniae CAP was documented by direct pulmon-
ary microbiological sampling in 150 (68%) cases (tracheo-
bronchial aspirates, n = 76; blind protected telescoping
catheter, n = 40; sputum examination, n = 24; broncho-
alveolar lavage, n = 10). Pleural effusion was also positive
in 12 patients and urinary antigen in 58 patients. In 28
patients, the latter examination was the only diagnostic
method with a positive result. As commonly reported in
pneumococcal pneumonia, positive blood culture was
found in 101 patients (45.5%), and was the single micro-
biological proof in 33 patients. It is noteworthy that
patients with or without bacteraemia had similar organ
failure features (Table 2). Co-infection with other bac-
teria was demonstrated in just 12 patients. Nosocomial
infections occurred in 69 patients during the ICU stay.
The prevalence of S. pneumoniae strains with
decreased susceptibility to penicillin was 39.7% (n = 77),
and resistance rates for macrolides and fluoroquinolones
were 54% and 1% respectively. Initial antibiotherapy was
adequate against S. pneumoniae in 92.3% (179 patients
out of 194, after exclusion of patients with pneumococcal
CAP diagnosed simply with positive urinary antigen). As
recommended by international guidelines for severe CAP
treatment, antimicrobial therapy including macrolides
was initiated in a large proportion of the population (163
patients, 73.4%).
Outcome and prognostic factors
The median ICU length of stay was 13 (6 to 25) days. The
ICU mortality rate was 26.6% (n = 59 patients), including
15 patients who died within the first five days. The overall
hospital mortality rate was 28.8% (n = 64 patients). Causes
of ICU mortality were multi-organ failure (n = 38), refrac-
tory hypoxemia (n = 10), withdrawal or withholding of life
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support (n = 7) and persistent neurological failure (n = 4).
ICU mortality was not significantly lower in early ICU
admissions (22.6% of ICU referrals within 12 hours of onset
of infectious or respiratory symptoms vs. 27.5% of admis-
sions after a delay of more than 12 hours, P = 0.41). Inter-
estingly, ICU mortality was 31.1% when at least one of the
two major criteria of the American Thoracic Society was
present (n = 190), whereas all patients with at least two of
the three minor ATS/IDSA criteria survived (n = 32).
In univariate analysis, clinical variables associated with
increased mortality included age; male gender; co-mor-
bidities, such as cirrhosis, chronic heart failure and can-
cer; the SAPS II; organ dysfunctions such as ARDS and
septic shock; organ support, such as mechanical ventila-
tion and renal replacement therapy; biological disorders
(lactate, coagulation disorders) and adjunctive therapies
(low dose corticosteroids and association of antibiotics)
(Table 1). In order to identify independent prognostic









Age 60 (49-75) 59 (48-70) 67 (54-80) 0.003
Male gender, n (%) 146 (66) 96 (57) 50 (78) 0.014
Underlying conditions
Tobacco use, n (%) 89 (40) 62 (37) 27 (42) 0.5
Alcohol abuse, n (%) 65 (29) 44 (26) 21 (33) 0.34
COPD, n (%) 57 (26) 36 (21) 21 (33) 0.08
Immunosuppressive treatment, n (%) 49 (22) 32 (19) 17 (26) 0.36
Cirrhosis, n (%) 14 (6) 5 (3) 9 (14) 0.002
Diabetes mellitus, n (%) 32 (14) 21 (12) 11 (17) 0.43
Chronic heart failure, n (%) 23 (10) 10 (6) 13 (20) 0.002
Chronic renal insufficiency, n (%) 12 (5) 6 (3) 6 (9) 0.1
Asplenia, n (%) 3 (1) 2 (1) 1 (2) 0.86
Systemic disease, n (%) 11 (5) 7 (4) 4 (6) 0.56
Cancer, n (%) 23 (10) 12 (7) 11 (17) 0.03
Long-term steroid therapy, n (%) 29 (13) 20 (12) 9 (14) 0.68
Clinical feature
SAPS II 47 (36-64) 43 (34-56) 63 (49 75) < 0.001
Septic shock, n (%) 170 (76) 107 (64) 63 (98) < 0.001
ARDS, n (%) 100 (45) 57 (34) 43 (67) < 0.001
Ventilator-acquired pneumonia, n(%) 69 (31) 50 (32) 19 (30) 0.87
Bacteraemia, n (%) 101 (45) 73 (43) 28 (31) 0.71
Penicillin-susceptible S. pneumoniae strain, n (%) (over 194 patients) 117 (60) 83 (53) 34 (53) 0.99
Main laboratory findings on admission
PaO2/FiO2 ratio 98 (73-149) 100 (75-156) 91 (61-128) 0.12
Lactate (mmol/L) 2.9 (1.6-5.9) 2.2 (1.3-5.6) 5.16 (2.6-9.1) 0.02
Glycaemia (mmol/L) 8.3 (5-13) 8.3 (4.9-12.6) 7.3 (4.9-11.2) 0.7
Urea (mmol/L) 10.7 (6.8-16.7) 9.3 (6.3-14.5) 12 (9.3-20.3) 0.13
Platelet count < 10,0000/mm3, n (%) 52 (23) 32 (19) 20 (31) 0.05
Leukocytes < 1000/mm3, n (%) 56 (25) 32 (19) 22 (34) 0.05
Prothrombin time < 50%, n (%) 55 (25) 30 (18) 25 (39) < 0.001
Bilirubin > 25 mmol/L, n (%) 59 (27) 26 (15) 23 (36) 0.001
Treatments
Mechanical ventilation, n (%) 186 (84) 123 (73) 63 (98) < 0.001
Renal replacement therapy, n (%) 70 (32) 30 (18) 40 (62) < 0.001
Antibiotherapy combination including macrolides, n (%) 163 (73) 110 (65) 53 (83) 0.04
Low-dose steroids, n (%) 69 (31) 41 (24) 28 (31) 0.001
Activated protein C, n (%) 44 (20) 32 (19) 12 (19) 0.78
Data are expressed as median and interquartile range. COPD: chronic obstructive pulmonary disease; SAPS: Simplified Acute Physiology Score; ARDS: acute
respiratory distress syndrome; S.pneumoniae: Streptococcus pneumonia.
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factors, we performed a multivariate analysis that
included significant variables from the univariate analy-
sis. Because of its co-linearity with several variables, the
SAPS II was not included in the final model. Age, male
sex and renal replacement therapy were identified as
independent predictors of hospital mortality (Table 3).
In contrast, shock (OR 12.1, 95% CI 0.78, 187.19), acute
kidney injury (OR 1.01, 95% CI 0.48, 2.17), thrombocy-
topenia (OR 1.74, 95% CI 0.54, 5.66), leukopenia (OR
1.03, 95% CI 0.39, 2.69) and low-dose steroids use (OR
1.34, 95% CI 0.61, 2.96]) were not significantly asso-
ciated with hospital mortality.
Discussion
We report here the most important cohort of pneumo-
coccal pneumonia requiring ICU management. The
strength of our study is that we studied a homogenous
population, including patients with only microbiologi-
cally documented S. pneumoniae CAP, with exclusive
pulmonary infection and reviewing of the patients’ files
by two independent investigators. Moreover, we chose
to eliminate aspiration pneumonia or chronic obstruc-
tive pulmonary disease (COPD) exacerbated by S. pneu-
moniae colonisation. We used a multicentre cohort,
reflecting both university (tertiary referral) and non-uni-
versity hospitals with a wide scope of hospital sizes,
locations and practice environments.
It is striking that underlying co-morbidities have no
impact on outcome, even if some of them have been
demonstrated to increase the incidence of invasive pneu-
mococcal disease [21]. If tobacco and alcohol abuse were
more frequent in the pneumococcal CAP than in the
general population, they did not influence the course of
the infection. Similarly, respiratory failure and septic
shock were the main admission motives, but they were
not independent prognostic variables. In contrast, male
gender, age and need for renal replacement therapy were
overwhelmingly independent risk factors for mortality. In
a set of 43 patients with severe pneumococcal pneumo-
nia, death was driven by organ failure rather than co-
morbidity [10]. In another group of 137 ICU patients,
Georges et al. showed similar results, except for renal
Figure 1 Seasonal variation in ICU admission for severe pneumococcal community-acquired pneumonia.






Septic shock 76 (76) 94 (78) 0.69
Mechanical ventilation 83 (83) 103 (85) 0.46
ARDS 51 (51) 49 (40) 0.17
Acute kidney injury 36 (36) 51 (42) 0.33
Need for renal replacement therapy 35 (35) 35 (29) 0.46
72 (72) 85 (70) 0.83
Multi-organ failure 26 (26) 33 (28) 0.77
ICU mortality
Hospital mortality
28 (28) 36(28) 0.71
Data are expressed as n (%). ARDS: acute respiratory distress syndrome.
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replacement therapy [9]. These authors reported that leu-
copenia, nosocomial infections and inadequacy of initial
antimicrobial therapy were other risk factors for death. In
our study, none of these factors were associated with
adverse outcomes. Astonishingly, male gender had a
major impact on outcome. This is in line with the higher
mortality rate of sepsis in male patients despite lower
incidence than in female patients [22]. Underlying hor-
monal-, social- or disease-associated mechanisms remain
to be explored to explain these findings [23].
Pneumococcal pneumonia requiring ICU admission is
associated with a high rate of fatality, with more than one
fourth of the patients dying in hospital. The highest pro-
portion of death occurs early in the course of the disease,
despite an excellent proportion of initial adequate anti-
biotherapy [24]. This is considered to be related to the
early inflammatory process, which is overwhelming host
defences. In a recent study, Garcia-Vidal et al. investi-
gated independent factors associated with early deaths in
CAP and demonstrated that age, altered mental status,
multilobar pneumonia, shock, bacteraemia and inade-
quate empiric antibiotic therapy were predictors of death
within 48 hours [25]. The small number of patient dying
in the first two days in our cohort did not allow us to
perform similar analysis.
The present study confirmed that S. pneumoniae pneu-
monia-related bacteraemia is not associated with a worse
outcome. Clinical features and organ failures prevent
identification of bacteraemic and non-bacteraemic
patients (Table 2). This observation is similar to previous
reports [26,27] including the study from Bordon et al.
who investigated a cohort of 1,847 patients, including
125 patients with bacteraemia, and found that prognosis
was not influenced by S. pneumoniae bloodstream infec-
tion [27]. Our findings are in line with prior investiga-
tions, suggesting that presence of pneumococcal
bacteraemia might not be a contraindication for de-esca-
lation and short duration of antibiotherapy in clinically
stable patients.
As recommended by international guidelines [28],
initial antibiotherapy in the setting of severe CAP must
include a b-lactamin active against S. pneumoniae. As a
result, the rate of adequate antibiotherapy is usually high,
as reported in our study. Consequently, improvement of
antibiotherapy delivery is unlikely to improve the out-
come of pneumococcal pneumonia. Thus, adjuvant
therapies might have a determinant role to reduce mor-
tality rate [9,24,29]. In our study, we failed to demon-
strate that use of activated protein C was associated with
a better outcome, despite the suggestion by Laterre et al.
that its use was of particular interest during S. pneumo-
niae pneumonia in the Prowess study [30]. However, the
recent Prowess Shock study did not replicate these
results and led to drug retrieval [31]. Similarly, the Capti-
vate study was the largest clinical trial conducted on
severe CAP and examined the recombinant tissue factor
pathway inhibitor. With 694 proven cases of pneumococ-
cal pneumonia, the study failed to demonstrate any bene-
fit on survival in either the whole population or the
pneumococcal subgroup [32].
Low-dose steroids represent another controversial
therapy in severe sepsis. Some studies suggest this treat-
ment improves survival in critically ill patients with
severe CAP [33]. In contrast, others, such as Snijders
et al., who compared the administration of corticoster-
oids plus antibiotics, vs. antibiotics alone in severe sep-
sis, reported no benefit with steroids [34]. The low
number of treated patients, the observational character-
istics of our study and the variability of steroid use
between the participating centres preclude drawing any
conclusions. However, in the present study, low doses of
steroids were associated with increased mortality in uni-
variate analysis. With the findings of the Corticus study,
low-dose steroids should be restricted to patients with
refractory septic shock [35].
Association of b-lactamin and either a macrolide or a
fluoroquinolone has been linked with a lower mortality
in severe CAP [8,36]. However, the clinical impact of
such a combination is seriously debated, and may vary
among pathogens. For S. pneumoniae, combined antibio-
tic therapy might be beneficial to treat undiagnosed co-
infections, or through anti-inflammatory properties of
macrolides. However, these data emerged essentially
from retrospective or small prospective studies [8,36-42],
and are challenged by several other reports [43-48] as
with our study, and will have to be confirmed in a multi-
centre randomized study. To date, the recommendation
of dual antibiotherapy for S. pneumoniae CAP has not
been endorsed by scientific societies.
Pneumococcal pneumonia occurred preferentially dur-
ing autumn or winter. This phenomenon has already
been described in non-critically ill patients, with a clear
link to external temperature [49] and concomitant
respiratory viral infections [50]. Here we report for the
first time this seasonality in ICU pneumococcal CAP.
Interestingly, the severity of pneumonia assessed by the
mortality rate was not influenced by season.
We found that S. pneumoniae strains with diminished
susceptibility to penicillin were involved in almost 40% of
cases. This is consistent with the recent report from the
Table 3 Multivariate analysis of factors associated with
hospital mortality
Odds ratio (95% CI) P
Male sex 2.83 (1.16, 6.91) 0.01
Age 1.05 (1.02, 1.08) 0.026
Renal replacement therapy 3.78 (1.71, 8.36) 0.001
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French national reference centre for S. pneumoniae,
which collects isolates from invasive pneumococcal dis-
eases [51]: the overall proportion of strains that are non-
susceptible to penicillin decreased from 45% to 35% in
adults between 2001 and 2006. Interestingly, we con-
firmed in this severe ICU population that penicillin resis-
tance did not influence outcome, as previously described
in less severe populations [52,53].
A few limitations deserve careful consideration. First,
despite prospective data acquisition, there were some
missing data, as illustrated by the lack of information
about influenza or pneumococcal vaccination or HIV sta-
tus. Moreover, we did not have access to the time lag
between symptom onset and antibiotherapy initiation,
which has been proposed as a major outcome determinant
[54]. Second, due to the multicentre design, therapeutic
strategies (that is, antimicrobial therapy, ventilation proto-
cols and adjunctive therapies) were not standardised.
Third, we used the 2001 American Thoracic Society
guidelines for severe CAP definition, which included three
minor criteria, rather than the 2007 ATS/IDSA definition
that includes nine minor criteria [28]. Phua et al. investi-
gated the prognostic value of minor criteria for ICU
admission, according to the 2007 guidelines, and found
that mortality rose from 0.9% with no risk factors to 35.2%
for patients with at least three minor criteria [55]. This
underlines the large improvement of determination of
prognosis provided with the 2007 criteria, as compared
with the initial one that we used. Unfortunately, several of
the new minor criteria were not present in our databases.
Fourth, we could not study the serotypes of S. pneumoniae
in our analysis, and strain specificities seem to be a major
element of severity [56]. This requires specific investiga-
tions, which were not routinely performed. Similarly, bio-
markers such as C-reactive protein or procalcitonin were
not available in the databases, whereas routine use of these
biomarkers has been shown to improve the triage score for
CAP patients in the emergency department [57]. As all
our patients were hospitalised in the ICU, the interest of
such predictor tools remains to be demonstrated in this
population.
Conclusions
In summary, we conducted a multicentre observational
study of the epidemiology and outcome of pneumococ-
cal CAP in a large homogeneous cohort of critically ill
patients. We highlighted that S. pneumoniae pneumonia
was still associated with a poor outcome, with high early
mortality, despite adequate antimicrobial therapy. In the
future, determination of factors related to the host, that
is, genetic susceptibility, and to the bacteria, that is,
virulence, is likely to be crucial for a better understand-
ing of the pathophysiology of invasive pneumococcal
pneumonia [58].
Key messages
• Despite a high proportion of adequate antibiother-
apy, mortality in patients with severe pneumococcal
CAP admitted to the ICU reaches 29 %.
• Microbiological specificities (penicillin susceptibil-
ity and concomitant bacteraemia) have no significant
impact on organ failure and mortality.
• Underlying co-morbidities do not impair survival
in the ICU, whereas age, male sex and need for
renal replacement therapy are associated with an
unfavourable outcome.
• Adjunctive therapies do not seem to influence the
impact of severe pneumococcal pneumonia.
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